Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2.
Trends Pharmacol Sci
; 41(11): 815-829, 2020 11.
Article
in English
| MEDLINE | ID: covidwho-709353
ABSTRACT
With the recent spread of severe acute respiratory syndrome coronavirus (SARS-CoV-2)_ infecting >16 million people worldwide as of 28 July 2020, causing >650 000 deaths, there is a desperate need for therapeutic agents and vaccines. Building on knowledge of previous outbreaks of SARS-CoV-1 and Middle East respiratory syndrome (MERS), the development of therapeutic antibodies and vaccines against coronavirus disease 2019 (COVID-19) is taking place at an unprecedented speed. Current efforts towards the development of neutralizing antibodies against COVID-19 are summarized. We also highlight the importance of a fruitful antibody development pipeline to combat the potential escape plans of SARS-CoV-2, including somatic mutations and antibody-dependent enhancement (ADE).
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Antibodies, Neutralizing
/
Immunotherapy
Type of study:
Randomized controlled trials
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Trends Pharmacol Sci
Year:
2020
Document Type:
Article
Affiliation country:
J.tips.2020.07.004
Similar
MEDLINE
...
LILACS
LIS